Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rayan Yousefzai

Advanced Heart Failure and Transplant Cardiology Houston, TX Medical Doctor

NPI 1629210273 CMS profile 1092714

6550 Fannin St Ste 1901, Houston, TX 77030

Open in the dashboard

General payments

$7,856

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$66,828 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Rayan Yousefzai of Houston, TX is reported in the CMS Open Payments database as having received $7,856 across 188 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $66,828 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 51st percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $994 23
2024 General $2,099 50
2023 General $2,161 57
2022 General $1,664 36
2021 General $589 9
2020 General $67 4
2019 General $282 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rayan Yousefzai
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Rayan Yousefzai were reported at $994. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Rayan Yousefzai Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $282 $863 $224–$4,562 $163
2020 $67 $452 $122–$3,992 $114
2021 $589 $550 $159–$3,571 $132
2022 $1,664 $729 $221–$4,357 $149
2023 $2,161 $1,002 $309–$5,827 $160
2024 $2,099 $931 $273–$5,204 $164
2025 $994 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,343 99 payments
  2. Abiomed $1,488 17 payments
  3. CVRx, Inc. $399 3 payments
  4. Alnylam Pharmaceuticals Inc. $368 17 payments
  5. Impulse Dynamics (USA) Inc. $313 5 payments
  6. Edwards Lifesciences Corporation $303 2 payments
  7. Actelion Pharmaceuticals US, Inc. $208 9 payments
  8. W. L. Gore & Associates, Inc. $207 1 payment
  9. BridgeBio Pharma, Inc. $193 5 payments
  10. AstraZeneca Pharmaceuticals LP $168 4 payments
  11. Other $866 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,828 186 payments
  2. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $1,645 42 payments
  2. Impella $1,214 13 payments
  3. CARDIOMEMS Heart failure $1,194 43 payments
  4. Barostim Neo System $399 3 payments
  5. ONPATTRO $368 17 payments
  6. OPTIMIZER Cardiovascular Device $292 4 payments
  7. OPTIMIZER Cardiovascular Device $292 4 payments
  8. CARDIOMEMS Structural Heart $277 8 payments
  9. UPTRAVI $208 9 payments
  10. OPSUMIT $208 9 payments
  11. Other $1,900 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,764

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$850,158

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

29.7%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 17 $394,344
Entresto Sacubitril/Valsartan Brand 170 $189,700
Jardiance Empagliflozin Brand 137 $120,858
Farxiga Dapagliflozin Propanediol Brand 62 $64,899
Eliquis Apixaban Brand 50 $49,555
Sirolimus Generic 11 $6,967
Tacrolimus Generic 37 $4,729
Potassium Chloride Generic 71 $2,741
Torsemide Generic 52 $1,571
Hydralazine Hcl Generic 99 $1,480

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$103,444

Medicare's payments for the services billed

Medicare patients

257

Average age 71

Services billed

881

93 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 75%
Atrial fibrillation 64%
Diabetes 61%
Arthritis 53%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $85
$85 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $81
$81 137 —
VYNDAQEL
  • PFIZER INC. $62
$62 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $38
$38 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record